Victory Capital Management Inc. Sells 155,144 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Victory Capital Management Inc. lessened its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 71.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 63,387 shares of the company's stock after selling 155,144 shares during the period. Victory Capital Management Inc. owned 0.13% of Amphastar Pharmaceuticals worth $2,354,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Pacer Advisors Inc. grew its holdings in Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares during the period. Wellington Management Group LLP acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at about $957,000. XTX Topco Ltd acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at about $674,000. Geode Capital Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 1.5% during the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock valued at $44,674,000 after buying an additional 14,015 shares during the last quarter. Finally, Glenmede Trust Co. NA grew its holdings in shares of Amphastar Pharmaceuticals by 145.3% during the third quarter. Glenmede Trust Co. NA now owns 37,884 shares of the company's stock valued at $1,839,000 after buying an additional 22,439 shares during the last quarter. Institutional investors own 65.09% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price objective for the company.

Remove Ads

Amphastar Pharmaceuticals Stock Up 1.4 %

Amphastar Pharmaceuticals stock traded up $0.38 during midday trading on Friday, hitting $28.29. 1,478,601 shares of the stock were exchanged, compared to its average volume of 426,109. Amphastar Pharmaceuticals, Inc. has a 52-week low of $25.89 and a 52-week high of $53.96. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of 9.43, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The business's 50-day moving average price is $32.07 and its 200-day moving average price is $40.71. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares of the company's stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 27.10% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.